Early Safety From A Phase I, Multicenter, Open-Label Clinical Trial Of Talimogene Laherparepvec (T-Vec) Injected (Inj) Into Liver Tumors In Combination With Pembrolizumab (Pem).

J. Randolph Hecht,Miklos Pless,Antonio Cubillo,Aitana Calvo,Hong Jae Chon,Chunxu Liu,Wendy Snyder,Emily Chan,Marya F. Chaney,Jason Alan Chesney, Aleix Prat

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 4|浏览24

暂无评分

摘要

3015Background: T-VEC is a genetically modified, oncolytic HSV-1 designed to selectively replicate within tumors and produce GM-CSF to enhance systemic antitumor immunity. The safety and efficacy o...

查看译文

关键词

pembrolizumab,liver tumors,clinical trial,open-label,t-vec

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要